About
Dr. Saif is an internationally renowned expert in gastrointestinal (GI) cancers, experimental therapeutics, and pharmacogenetics. He is recognized as a key opinion leader and a dedicated clinician. Over the past two decades, he has led numerous clinical trials, including those resulting in FDA-approved therapies for various tumor types. He has vast experience with phase I dose-defining and hypothesis-driven studies and has collaborated with leading institutions such as Yale, Columbia, and Cold Spring Harbor Laboratories.
Dr. Saif’s research is deeply rooted in translational studies in GI carcinogenesis, predictive biomarkers, and mechanisms of resistance to cancer therapeutics. His work has often involved collaborative “team science” projects and systems biology approaches to uncover genetic pathways and associated networks. He has also made significant contributions to research on fluoropyrimidine drugs, focusing on dihydropyrimidine dehydrogenase (DPD) deficiency, the uracil breath test, and thymidylate synthase genotyping, among other areas.
In addition to his clinical trial leadership, Dr. Saif has coordinated and co-led large-scale database analyses and served as a principal investigator (PI) for numerous national and international studies, many of which have been published in high-impact journals and laid the foundation for future clinical research. He has contributed to over 600 peer-reviewed publications, 75 abstracts, and 24 book chapters and serves on several editorial boards. Dr. Saif is a frequent speaker at national and international conferences and continues to serve on grant review committees worldwide